Photopheresis Product Market by Product (Closed System, Open System), Therapeutic Area (Autoimmune Diseases, Cutaneous T-cell Lymphoma, Graft Versus Host Diseases), End User - Global Forecast 2024-2030

Photopheresis Product Market by Product (Closed System, Open System), Therapeutic Area (Autoimmune Diseases, Cutaneous T-cell Lymphoma, Graft Versus Host Diseases), End User - Global Forecast 2024-2030


The Photopheresis Product Market size was estimated at USD 514.34 million in 2023 and expected to reach USD 552.19 million in 2024, at a CAGR 7.83% to reach USD 872.37 million by 2030.

Photopheresis products are medical devices used in a therapeutic procedure called photopheresis, primarily for treating diseases related to the immune system, such as cutaneous T-cell lymphoma, graft-versus-host disease, and certain autoimmune disorders. In this treatment, a patient's blood is collected and treated with a light-sensitive medication before being exposed to ultraviolet light. This process modifies the immune cells, which are then reinfused into the patient to help modulate the immune response in a beneficial way. The adoption of photopheresis products is largely driven by their efficacy in treating complex immune-related conditions for which there are limited treatment options. Additionally, ongoing clinical trials and research in expanding the indications of photopheresis, such as in the treatment of organ transplant rejections, are also raising the adoption of photopheresis products. However, the use of photopheresis faces several challenges. The procedure requires specialized equipment and trained personnel, limiting its availability. Moreover, the treatment is time-consuming and needs to be repeated at regular intervals, which can pose cost constraints for patients. Despite these issues, technological advancements could make the devices more efficient, portable, and user-friendly. Furthermore, integrating photopheresis with other treatment modalities could enhance its effectiveness, opening up new avenues for comprehensive therapeutic strategies.

Regional Insights

The market for photopheresis products in the Americas, particularly in the United States and Canada, is showing strong growth. This is driven by a well-established healthcare infrastructure, increased awareness about the benefits of photopheresis treatments, and a rising prevalence of autoimmune diseases. Additionally, regulatory support for advanced medical therapies in countries, including the United States also fuels market growth. Europe shows a robust performance in the market owing to advanced healthcare systems and the growing adoption of technologically advanced therapies. The presence of major market players and supportive health policies also contribute positively. In the Middle East and Africa, the market is developing, with improving healthcare facilities, rising economic development, and increased investments in the healthcare sector. Asia-Pacific is witnessing rapid growth in the photopheresis product market. Increasing healthcare expenditure, rising awareness of advanced therapeutic options, and improving healthcare infrastructure significantly contribute to this growth. Countries including China, Japan, and Australia are leading in the adoption of photopheresis owing to their strong healthcare systems and active government initiatives to incorporate advanced medical treatments.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Photopheresis Product Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

Rising prevalence of autoimmune and cancer diseases
Increased global healthcare spending and growing awareness about chronic diseases

Market Restraints

High costs associated with photopheresis treatments

Market Opportunities

Technological advancements in photopheresis products
Amalgamation activities between photopheresis product manufacturers and healthcare institutions

Market Challenges

Regulatory and reimbursement issues associated with photopheresis products and treatments

Market Segmentation Analysis

Product: Growing adoption of closed systems for increased patient safety
End User: Higher need for photopheresis products in hospitals to offer a comprehensive treatment environment

Market Disruption Analysis

Porter’s Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Photopheresis Product Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Photopheresis Product Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Fresenius Kabi Introduces Single-Needle Function in Amicus Separator

Fresenius Kabi has expanded the capabilities of its Amicus Separator by integrating a single-needle option alongside its existing dual-needle system. This innovation caters to the procedural preferences of healthcare providers in the application of extracorporeal photopheresis, a treatment method utilized for certain immune-mediated diseases.

Japan Approves Reimbursement for Mallinckrodt's CELLEX Photopheresis System in Treating Chronic GVHD

The Japanese government has officially sanctioned reimbursement for Mallinckrodt's CELLEX Photopheresis System, a medical device designated for treating chronic graft-versus-host disease (cGVHD). This authorization is a strategic enhancement of therapeutic options for patients suffering from this complex post-transplant condition, wherein the donor's immune cells attack the recipient's body.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Photopheresis Product Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Photopheresis Product Market, highlighting leading vendors and their innovative profiles. These include BioCardia, Inc., Bristol-Myers Squibb Company, Fresenius SE & Co. KGaA, Johnson & Johnson Services, Inc., Koninklijke Philips N.V., Macopharma, Mallinckrodt Pharmaceuticals, Merck & Co., Inc., Pfizer Inc., PIT Medical Systems GmbH, Sanofi S.A., Terumo Corporation, and Transimmune AG.

Market Segmentation & Coverage

This research report categorizes the Photopheresis Product Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
Closed System
Open System
Therapeutic Area
Autoimmune Diseases
Cutaneous T-cell Lymphoma
Graft Versus Host Diseases
Solid Organ Transplant Rejections
End User
Ambulatory Centers
Hospitals
Specialty Clinics
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of autoimmune and cancer diseases
5.1.1.2. Increased global healthcare spending and growing awareness about chronic diseases
5.1.2. Restraints
5.1.2.1. High costs associated with photopheresis treatments
5.1.3. Opportunities
5.1.3.1. Technological advancements in photopheresis products
5.1.3.2. Amalgamation activities between photopheresis product manufacturers and healthcare institutions
5.1.4. Challenges
5.1.4.1. Regulatory and reimbursement issues associated with photopheresis products and treatments
5.2. Market Segmentation Analysis
5.2.1. Product: Growing adoption of closed systems for increased patient safety
5.2.2. End User: Higher need for photopheresis products in hospitals to offer a comprehensive treatment environment
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Photopheresis Product Market, by Product
6.1. Introduction
6.2. Closed System
6.3. Open System
7. Photopheresis Product Market, by Therapeutic Area
7.1. Introduction
7.2. Autoimmune Diseases
7.3. Cutaneous T-cell Lymphoma
7.4. Graft Versus Host Diseases
7.5. Solid Organ Transplant Rejections
8. Photopheresis Product Market, by End User
8.1. Introduction
8.2. Ambulatory Centers
8.3. Hospitals
8.4. Specialty Clinics
9. Americas Photopheresis Product Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Photopheresis Product Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Photopheresis Product Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.3.1. Fresenius Kabi Introduces Single-Needle Function in Amicus Separator
12.3.2. Japan Approves Reimbursement for Mallinckrodt's CELLEX Photopheresis System in Treating Chronic GVHD
12.4. Strategy Analysis & Recommendation
13. Competitive Portfolio
13.1. Key Company Profiles
13.2. Key Product Portfolio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings